Drugs / LEQ506
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01106508 | Oct 2010 → Jun 2015 | medulloblastoma, skin basal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEQ506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01106508 ↗ |
| Known as | NVP-LEQ506 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3133037 ↗ |
| Action | Inhibit | “Smoothened homolog antagonist” CHEMBL3133037 ↗ |
| Modality | Small molecule | — CHEMBL3133037 ↗ |
| Route | Oral | “LEQ506 given orally on a daily dosing schedule” NCT01106508 ↗ |
| Target | SMO | “Smoothened homolog antagonist” CHEMBL3133037 ↗ |